B. Case 2 Profile: Patient with Progressive HER-2 MBC

During the course of the simulation oncologist learners ordered adverse event counseling for patients in case 1 and case (Figure 6) 24% more participants referred the patients for psychosocial counseling after clinical guidance (Figure 6).

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC. Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.

3.3% participants who made clinical decisions within the simulation and proceeded to the concluding debrief section, analyses of which are beyond the scope of this manuscript. A key finding from this study is the role of simulation-based instruction in improving oncologists' evidence-based clinical decisions in the management of HER2-positive MBC.  Remaining gaps include selection of the most appropriate agents and their sequencing is crucial to maximizing responses and survival in patients with HER2-positive MBC.